Topology of the microsomal glycerol-3-phosphate acyltransferase Gpt2p/Gat1p of Saccharomyces cerevisiae by Pagac, Martin et al.
 1 
Supporting information for 
Topology of the microsomal glycerol-3-phosphate acyltransferase Gpt2p/Gat1p 
of Saccharomyces cerevisiae 
Martin Pagac1,2,3, Hector M. Vazquez1, Arlette Bochud1, Carole Roubaty1,3, Cécile Knöpfli1, 
Christine Vionnet1, and Andreas Conzelmann1 
1Department of Biology, University of Fribourg, CH-1700 Fribourg, Switzerland;  
2Present address: College of Pharmacy, University of Hawaii, Hilo, USA  
3These authors contributed equally to the work. 
Correspondence: andreas.conzelmann@unifr.ch, Phone ++41263008631, Fax ++41263009735, 
Chemin du musée 10, CH-1700, Fribourg, Switzerland 
Supplemental experimental procedures 
Reagents. Zymolyase 20T was from Seikagaku Corporation (Tokyo, Japan), n-dodecyl-ß-D-
maltoside, EDTA-free protease inhibitor cocktail and Pefabloc SC (AEBSF) from ROCHE (no. 
11873580001 and 11429876001), anti-V5-HRP antibody from INVITROGEN, anti-HA from 
BabCO, anti-VSVG and anti-FLAG from SIGMA, anti-Kar2p from Santa Cruz Biotech. HRP-
labeled antibodies were visualized by using the UptiLight HRP blot substrate (UPTIMA, 
France). Ubiquitin (from bovine erythrocytes), L-histidinol, picrylsulfonic acid (TNBS), 
palmitoyl coenzyme A lithium salt, (C16-CoA, P9716) and Agarose-poly-L-lysine were 
purchased from SIGMA, sulfo-EMCS (6-maleimidocaproic acid sulfo-n-succinimidyl ester) and 
sulfo-GMBS (N-[-maleimidobutyryloxy]-sulfosuccinimide ester) from Toronto Research 
Chemicals and Vivaspin 500 (MWCO 3 kDa) from GE Healthcare. [14C]-L-glycerol-3-
phosphate disodium salt (ARC 0316) was obtained from ANAWA Trading SA, Wangen, 
Switzerland.  
Bioinformatics tools. Conserved amino acids and motifs in acyltransferase domains were 
obtained using http://pfam.sanger.ac.uk/family/PF01553#tabview=tab2) and 
http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml (Marchler-Bauer et al., 2011). Topology 
predictions were obtained from TOPCONS (http://topcons.net/index.php?about=octopus) and 
TMHMM 2.0 (http://www.cbs.dtu.dk/services/TMHMM/). Calculations of Gsmi for TMs were 
obtained from the G predictor at http://dgpred.cbr.su.se/index.php?p=TMpred (full protein scan 
using default settings, i.e. length correction turned on, allowing for TMs from 19 to 23 amino 
acids in length). If the full protein scan option did not show any potential TM, we used the 
option “G prediction” with options “length correction” and “allow subsequences” turned on. 
Surface exposure of amino acids was predicted using NetSurfP 
(http://www.cbs.dtu.dk/services/NetSurfP). 
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Plasmid construction. Plasmid pBF720 carrying Gpt2p-V5-His6 (having a N719D mutation) was 
generated by PCR amplification of GPT2 using genomic DNA from BY4742 as a template and 
in frame ligation into pYES2NT/B (INVITROGEN) containing a C-terminal V5-His6 tag. 
Correction of the N719D mutation by the QuikChange multi site method (STRATAGENE) 
yielded pBF733. All cysteine-mutated alleles of Gpt2p-V5-His6 were generated by the 
QuikChange multi site method (STRATAGENE) using pBF733 as a template with primers 
indicated in Table SII. For the construction of epitope tagged alleles of GPT2 we started from 
plasmid pBF720. A BamHI site was inserted after amino acid 235 of GPT2 using crossed PCR. 
For this, GPT2 fragments 1 – 235 and 236 -743 were generated with PCR using primers 966 + 
969 or 968 + 967 (Table SII), respectively, containing an additional BamHI site after amino acid 
235. The two PCR fragments were cut with HindIII/BamHI or BamHI/NotI and ligated into the 
pYES2/NT vector opened with HindIII and NotI, pretreated with calf intestinal alkaline 
phosphatase. This triple ligation yielded a GPT2 version with a V5-epitope and a His6 tag at the 
C terminus and a BamHI site after amino acid 235. A double stranded HA-epitope and a double 
stranded VSVG-epitope, flanked by BamHI sites on each side were obtained through separate 
oligonucleotide synthesis of both strands, mixing equimolar amounts, heating to 94 °C and 
letting cool down. The vector and double stranded oligonucleotides were digested with BamHI; 
the vector was digested with shrimp alkaline phosphatase, mixed with 2-6-fold molar excess of 
digested double-stranded oligonucleotides and ligated. This yielded Gpt2p-235HA-V5-His6 and 
Gpt2p-235VSVG-V5-His6 (pBF223 and pBF225) having the respective epitopes flanked by 
Gly-Ser on each end, inserted between amino acids 235 and 236. The same strategy was used to 
insert tags after amino acid 412 of GPT2 (pBF227 and pBF228), using primers 966 + 971 and 
970 + 967 (Table SII). For all cysteine mutated alleles and tag insertion alleles, the entire 
reading frame was verified by sequencing; for DTR constructs the inserted N-terminal fragments 
of GPT2 or SCT1 were sequenced and errors were corrected using the QuikChange multi site 
method (STRATGENE) except for a conservative I53V mutation in Gpt2p-P467-DTR and a 
V248A mutation in Sct1p-P459-DTR. Sequencing was done by MICROSYNTH, Balgach, 
Switzerland.  
Preparation of microsomes. Cells were grown to an A600 of 3-6. Cells were washed with ice-cold 
10 mM NaN3, resuspended in zymolyase buffer (10 mM NaN3, 1.4 M sorbitol, 50 mM 
potassium phosphate, pH 7.5, 40 mM -mercaptoethanol, 1 mg ml-1 zymolyase 20T) and 
incubated for 1-2 h at 30 °C without shaking. Spheroplasts were collected by centrifugation at 
800  g for 5 min at 4 °C and washed with one volume of zymolyase buffer lacking -
mercaptoethanol and zymolyase. For experiments using PEG-mal or UBI-mal, NaN3 and -
mercaptoethanol were omitted. Spheroplasts were lysed in buffer A (0.2 M sorbitol, 5 mM 
MgCl2, 0.1 M potassium phosphate, pH 7.4) supplemented with 2 mM EDTA, 10 μg ml
-1 
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leupeptin, 2 μg ml-1 aprotinin, 5 μg ml-1 pepstatin A, 2 mM PMSF, 2 mM AEBSF, 1 x EDTA-
free Roche protease inhibitor cocktail, and 50 μg ml-1 DNAse by vortexing for 1 min and forcing 
them 10 times through a 0.4 mm gauge needle. After centrifugation at 800  g for 5 min at 4 °C, 
the supernatant was filtered through Millipore Millex AP-20, then centrifuged at 16,000  g for 
30 min at 4 °C to pellet the microsomes. The supernatant was discarded; microsomes were 
resuspended in small volumes of buffer A.  
Synthesis of Ubiquitin-EMCS and Ubiquitin-GMBS (UBI-mal). Ubiquitin is a 76 amino acids 
long (8.5-kDa) protein, which does not contain any cysteine but 7 lysine residues. It was 
conjugated with the heterobifunctional crosslinkers sulfo-EMCS or sulfo-GMBS, each carrying 
two different groups, a maleimide and a N-hydroxysuccinimide (NHS) ester reacting with 
sulfhydryl and primary amino groups, respectively. This yielded a highly water-soluble, entirely 
membrane-impermeable cysteine labeling reagent, ubiquitin-maleimide (UBI-mal). Sulfo-EMCS 
and sulfo-GMBS were stored desiccated at -20°C. Vivaspin 500 (MWCO 3 kDa) columns and 
were washed with buffer E (50 mM NaH2PO4/Na2HPO4, pH 7.2) prior to use. 25 mg (= 2.92 
μmol) of ubiquitin were dissolved in a final volume of 760 μl buffer E and transferred to the 
reaction tube containing 2.4 mg (= 5.85 μmol) Sulfo-EMCS dissolved in 870 μl buffer E. The 
reaction mixture was incubated for 30 min at room temperature on a wheel. Excess (non-reacted) 
cross-linker was removed from the mixture by concentrating the solution in a Vivaspin 500 
column, washing twice with buffer E, then concentrating to a volume of 849 μl. 131 μl 1.5 M 
sorbitol (0.2 M final) were added, and the resulting 3 mM ubiquitin-EMCS solution was either 
used immediately for the cysteine labeling experiments or stored as frozen aliquots at -20°C. 
GMBS was coupled in the same way but using buffer F (250 mM KCl, 10 mM NaCl, 8 mM 
Na2HPO4, 2 mM KH2PO4, pH 7.2) and uncoupled GMBS was removed at the end by adding a 10 
fold molar excess of lysine in the form of prewashed Agarose-poly-L-lysine and further 
incubation for 15’ at room temperature. Agarose-poly-L-lysine was removed by centrifugation. 
All experiments were performed with ubiquitin-EMCS except for Fig. S1B, where ubiquitin-
GMBS was used. 
Cysteine accessibility assay using UBI-mal. To probe the accessibility of the cysteines of Gpt2p, 
several technical problems had to be solved. The traditional cysteine accessibility methods rely 
on the use of small impermeant alkylating reagents (Bogdanov et al., 2005). It however has been 
reported that the ER membranes of mammalian cells are permeable for such small reagents, 
unlike lysosomal, Golgi or plasma membranes. Yet, ER membranes were not permeable to 
polyethyleneglycol-5000-maleimide (PEG-mal)(Le Gall et al., 2004). As judged by the 
derivatization of Kar2p, an ER lumenal soluble protein possessing a single cysteine residue, our 
yeast ER microsomes are permeable for PEG-mal at room temperature, are usually tight at 0 °C 
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or 4°C (Fig. S1A), but not in all experiments. Ubiquitin maleimide (UBI-mal) on the other hand 
was found to be impermeant even at room temperature (Fig. S1B). From a given cell line, 4 
aliquots of 50 μg microsomal proteins were resuspended in 100 μl buffer, 2 aliquots in buffer G 
(0.2 M sorbitol, 5 mM MgCl2, 100 mM NaH2PO4/Na2HPO4, pH 7.2), one in buffer H (= Buffer 
G + 1% w/v DDM), one in buffer I (= Buffer G + 1% w/v SDS). Samples were preincubated for 
30 min on ice-cold water (0°C), except microsomes in buffer I, which were incubated at room 
temperature. 50 μl (150 nmol) of UBI-mal (ubiquitin-EMCS) or, for control, 50 μl of buffer G 
were added. After a further 30 min at the same temperature, the reactions were stopped by 
addition of 25 mM DTT and further incubation for 15 min. Samples were heated for 20 min at 
65°C in Laemmli sample buffer and separated by SDS-PAGE. Proteins were transferred on a 
PVDF membrane using 25 mM Tris, 192 mM glycine, pH 8.3 as buffer; Western blotting was 
performed using anti-V5, anti-Kar2p, and anti-FLAG antibodies.  
Phosphopeptide analysis. For the preparation of large amounts of Gpt2p we adapted a published 
protocol (Drew et al., 2008) as follows: BY4742 cells harboring pBF733 (GAL1UAS-GPT2-V5-
His6 in pYES2NT/B with C-terminally tagged WT GPT2) were pre-cultured in 20 ml of YNB 
2% galactose, then in 200 ml of YNB 2% glucose. 3x 2L of YNB 0.1% glucose were inoculated 
to give an A 600 of 0.12 and grown overnight at 30°C to an A600 of about 1. Galactose (2% final) 
was added to induce protein expression for 2h at 30°C, during which the A600 rose to between 2 
and 2.5). All media lacked uracil, to maintain the plasmid. The cells were harvested at 4°C, then 
washed twice in buffer B (50 mM KH2PO4/K2HPO4 pH 7.5, 1 mM EDTA, 0.6M sorbitol, 1x 
Roche Complete EDTA-free protease inhibitors cocktail) and the cell pellets (about 2 x 6'000 
A600 units of cells (equivalent to 6'000 ml of culture having an A600 of 1)) were frozen in liquid N2 
and stored at -20°C. 
Cell pellets were thawed on ice and resuspended to 200 A600 units ml-1 of fresh buffer C (0.2M 
sorbitol, 50 mM Na2HPO4/NaH2PO4 pH 6.0, 5 mM MgCl2, 20 μg ml
-1 DNase, 2 mM PMSF, 
1x Roche Complete EDTA-free protease inhibitors cocktail, pepstatin A 5 μg ml-1, 5 mM 
iodoacetamide). A volume of glass beads was added to two volumes of cell suspension, and 
the cells were broken in a planetary mono mill (Fritsch Pulverisette 6, Idar-Oberstein, 
Germany) at 4°C. The beads were filtered and the lysate centrifuged at 1000 g, 4°C, for 5 min 
to remove cell debris and nuclei. The membranes were pelleted by ultracentrifugation 
(Sorvall Discovery M120) at 150'000 g, 4°C, for 2h, then resuspended in 4 ml of buffer D 
(0.2M sorbitol, 50 mM Na2HPO4/NaH2PO4 pH 6.0, 5 mM MgCl2, 100 mM CaCl2, 1 mM 
PMSF, 1x Roche Complete EDTA-free protease inhibitors cocktail, pepstatin A 5 μg ml-1). 
The membranes were diluted to 3.5 mg protein ml-1 of buffer E (8 mM Na2HPO4 1.4 mM 
KH2PO4, 10 mM imidazole pH 8.0, 436 mM NaCl, 2.6 mM KCl, 10% glycerol, 0.9 mM 
Triton X-100 (0.0562 % (w/v)), 1 x Roche Complete EDTA-free protease inhibitors cocktail, 
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5 μg ml-1 pepstatin) and more Triton X-100 was added for complete solubilization (20 x the 
amount of microsomal proteins). The volume was adjusted with buffer E to reduce the Triton 
X-100 concentration to 2%, and the membranes were solubilized for 2 h on a rotating wheel, 
at 4°C. Insoluble material was sedimented by ultracentrifugation (45 min at 100'000 g, 4°C). 
One ml of QIAGEN Ni-NTA superflow resin, pre-equilibrated with binding buffer, was 
added to the solubilized membranes and the binding reaction was performed overnight at 4°C, 
on a wheel. The lysate and resin were poured into 5 ml gravity-flow columns with a filter of 
30 μm pore diameter (Pierce, Thermo Scientific, 89897). The flow-through was reloaded a 
second time; non-binding proteins were washed away by first adding 5 column volumes of 
buffer E and then 4 column volumes of buffer E with 20 mM imidazole. The bound material 
was eluted by adding 2 x 2 ml of buffer E containing 250 mM imidazole. Part of the first 
elution (2 μg protein μl-1) was immediately heated for 15 min at 65°C in sample buffer, the 
rest was frozen as aliquots in liquid nitrogen and stored at -20°C. Purification was monitored 
by Bradford assay of protein content, by Western blotting, and by colloidal Coomassie blue 
(Sigma) staining of 7% SDS gels. 40 μl of the first elution in sample buffer was separated on 
a 7% SDS gel (1.5 mm). The gel was stained during 15 min with Coomassie G250 (Serva) 
without fixing. Both bands corresponding to hyper- or hypo- phosphorylated Gpt2p were cut, 
frozen in liquid nitrogen and used for mass spectrometric analysis. 
Bands were excised from SDS-PAGE gel and digested, as described (Shevchenko et al., 
1996; Wilm et al., 1996), with sequencing-grade trypsin (Promega).  
Extracted peptides were analyzed on a hybrid LTQ Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific, Bremen, Germany) interfaced to an Ultimate 3000 RSLC nano 
HPLC system (Dionex, Olten, Switzerland). Solvents used for the mobile phase were 97:3 
H2O:acetonitrile (v/v) with 0.1 % formic acid (A) and 20:80 H2O:acetonitrile (v/v) with 0.1 % 
formic acid (B). Each sample was injected twice on the Orbitrap mass spectrometer, using 
either CID or HCD for peptide fragmentation. 
Peptides were loaded onto a trapping microcolumn Acclaim PepMap100 C18 (20 mm x 100 
m ID, 5 m, Dionex) in H2O:acetonitrile 97:3 (v/v) + 0.1 % formic acid at a flow rate of 3.5 
l min-1. After 12 min, they were back-flush eluted and separated on a reversed-phase 
nanocolumn Acclaim PepMap RSLC 100A (75 m ID x 25 cm, 2 m, Dionex) at a flow rate 
of 300 nl min-1 with a gradient from 6 to 72 % acetonitrile in 0.1% formic acid (total run time: 
95 min). 
For spraying, an uncoated needle (New Objective silicatipsTM, 20 m ID, 10 m tip ID) was 
used with a voltage of 2.9 kV, and the mass spectrometer capillary transfer temperature was 
set at 300°C. Lock mass option was used for full MS scan recalibration with a 
polydimethylcyclosiloxane ion from ambient air (m/z 445.12003). Data-dependent acquisition 
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was controlled by Xcalibur 2.1 software (Thermo Fisher Scientific). In CID mode, the 20 
most intense precursor ions detected in the full MS survey performed in the Orbitrap (range 
350-1500 m/z, resolution 60’000 at m/z 400) were selected and fragmented. MS/MS was 
triggered by a minimum signal threshold of 3’000 counts, carried out at relative collision 
energy of 35 %, with isolation width of 4.0 amu and wideband activation, and fragment ions 
were analyzed in the ion trap. In HCD mode, the 15 most intense precursor ions detected in 
the full MS survey performed in the Orbitrap (range 300-1700 m/z, resolution 30’000 at m/z 
400) were selected and fragmented. MS/MS was triggered by a minimum signal threshold of 
3’000 counts, carried out at relative collision energy of 40 %, with isolation width of 1.7 amu, 
and fragment ions were analyzed in the Orbitrap at a resolution of 7’500. Only precursors 
with a charge higher than one were selected for fragmentation and the m/z of fragmented 
precursors was then dynamically excluded from any selection during 25 s. From raw files, 
MS/MS spectra were exported as mgf files (Mascot Generic File, text format) using 
extract_msn script (Thermo Fisher Scientific). 
All MS/MS samples were analyzed using Mascot 2.3 (Matrix Science, London, UK). Mascot 
was set up to search the SwissProt database (release 2011_03, www.uniprot.org,) restricted 
to Saccharomyces cerevisiae taxonomy (7’320 sequences after taxonomy filter), and a custom 
database containing usual contaminant proteins (digestion enzymes, keratins, etc.). Trypsin 
(cleavage at K, R) was used as the enzyme definition. Mascot was searched with a fragment 
ion mass tolerance of 0.5 Da for CID data and 0.02 Da for HCD data, a parent ion tolerance 
of 10 ppm, allowing 2 missed cleavages. Iodoacetamide derivative of cysteine was specified 
in Mascot as a fixed modification. Acetylation at the proteins' N-terminal end, deamidation of 
asparagine and glutamine, oxidation of methionine, and phosphorylation of serine, threonine 
and tyrosine were specified as variable modifications. Phosphosite localization was based on 
Mascot Delta Score described before (Savitski et al., 2011). 
GPAT assay. Sct1 cells were grown in YPD to stationary phase. Microsomes were prepared by 
breaking cells with glass beads in buffer A supplemented with 2 mM EDTA. Cell walls were 
removed by centrifugation for 5 min at 800 g, 4 °C, the supernatant was filtered through a 0.8 
μm glass fiber filter (Millipore, Millex-AP, AP20) and the microsomes were sedimented by 
centrifugation at 16’000 x g for 30 min, 4 °C. 100 μg microsomal proteins were diluted into 
buffer A and preincubated for 15 min at 0 °C with acyl-CoA (22.5 μM C16:0-CoA and 22.5 μM 
C18:1-CoA final conc.), DTT (1 mM final conc.) and with or without Triton X-100 (0.1% v/v) 
and further incubated for 45 min after addition of TNBS. GPAT activity was measured in a 200 
μl assay volume by adding 0.2 μCi of [14C]glycerol-3-phosphate diluted with cold G3P to a 
specific activity of 5 mCi mmol-1 at room temperature for 20 min. Reactions were stopped by 
adding 600 μl CHCl3/MeOH (1/1), 200 μl CHCl3 and 320 μl 1% HClO4. The lower organic 
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phase was washed 3 times with 400 μl 1% HClO4, and samples were analyzed by TLC in 
CHCl3/MeOH/acetic acid/5% aqueous sodium bisulfite (67/26/4.4/2.6). Plates were analyzed by 
phosphorimaging and radioscanning (Berthold Services GmbH, Switzerland). Control 
experiments showed a) that GPAT activity was linear for at least 10 min over a range of 
microsomal protein concentrations, b) that the product is stable (Fig. S7A, B), and c) that even at 
the end of a 20 min incubation, most of radioactivity still is in the form of G3P (Fig. S7C). 
 
Supplemental Figure legends 
Fig. S1. Permeability of yeast microsomes for PEG-maleimide. A, microsomes from BY4742 
WT cells were incubated in the absence or presence of DDM (D) or SDS (S) with PEG-mal (5 
mM) for indicated time spans (min) either at 0 °C (upper panel) or at room temperature (lower 
panel). Untagged and mass-tagged Kar2p was observed after SDS/PAGE and Western blotting 
using anti-Kar2p antibody. Note that Kar2p has a single cysteine residue, derivatization of which 
induces a mass shift of about 10 kDa. B, microsomal membranes derived from WT BY4742 
cells were prepared as above. In this experiment the membrane pellet was resuspended and 
incubated for 15 minutes with 200 μM -mercaptoethanol. Re-centrifuged microsomes were 
then incubated in the presence or absence of detergent with freshly prepared ubiquitin-GMBS 
(0.9 mM) for 30, 60 and 90 minutes at room temperature.  
Fig. S2. Functionality of GPT2 alleles containing only one cysteine. Sporulation of diploid 
gpt2::TRP1/GPT2 sct1::HIS3/SCT1 (FBY2250) strains harboring URA3 plasmids containing 
either WT GPT2 or mutated GPT2 alleles yielded viable gpt2::TRP1 sct1::HIS3 (2) cells. A, 
2 cells harboring either WT GPT2 or GPT2 single-cysteine mutant alleles (all cysteines deleted 
except for a single cysteine at positions 77, 254 or 297) were plated on selective media 
supplemented with 1 M sorbitol, 5’-fluoroorotic acid (FOA) and containing galactose or 
raffinose as the carbon source as indicated. B, yeast cells containing the GAL1 promoter driven 
Gpt2p-V5-His6 construct were grown in raffinose at 30 °C, at time 0 galactose was added from a 
concentrated solution to induce Gpt2p-V5-His6. After a further culture for 0 to 2 hours, lysates 
were prepared and probed by Western blotting using anti-V5 antibody. 
Fig. S3. Functionality of cysteine mutated GPT2 alleles used in Fig. 3. A, model of Gpt2p 
topology with natural cysteines in orange, cysteine substitutions in loop L1-2 in turquoise. B-E, 
we constructed new gpt2 alleles containing only the cysteines indicated on top of each double 
panel in 2μ vectors behind the GAL1 promoter and followed by a C-terminal V5-His6 tag. Non-
natural cysteines are in bold. To test the functionality of the cysteine-modified alleles, the 
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vectors were introduced into a gpt2::TRP1/GPT2 sct1::HIS3/SCT1 diploid (FBY2250). After 
sporulation and tetrad dissection, we screened for growth of viable gpt2 sct1 progeny on 
galactose and glucose-containing medium. B, progeny from 3 complete tetratype tetrads having 
the indicated genotypes and harboring Gpt2p-5CS-C77-254-297-V5-His6 was streaked on YNB 
with galactose as a carbon source without and with 5’-fluoroorotic acid (FOA) as indicated. 
Plates were photographed after 3 days at 30°C. Genotypes were deduced by PCR and by growth 
on medium lacking His or Trp (YNBGal-His, YNBGal-Trp)(not shown). The critical gpt2 
sct1 (2) strains rescued by Gpt2p-5CS-C77-254-297-V5-His6 are highlighted in red. C – E, 
progeny from one complete or incomplete tetrad carrying a plasmid born gpt2 allele was 
precultured either in galactose or glucose for 16 h. Ten fold dilutions were then spotted onto 
YNB plates containing the same carbon source as the preculture. Plates were photographed after 
3 days at 30°C. Genotypes of the strains analyzed are on the left. A gpt2 sct1 strain rescued 
by WT GPT2 in the same vector was added for comparison to each tetrad progeny. 
Fig. S4. Functionality of GPT2 alleles used for cysteine accessibility studies in Fig. 4. 
Functionality was tested as described in Fig. S3C-E. 
Fig. S5. Viability of gpt2 sct1 cells containing epitope-tagged GPT2 alleles. A, sporulation 
of diploid gpt2::TRP1/GPT2 sct1::HIS3/SCT1 (FBY2250) strains harboring URA3 plasmids 
containing either WT GPT2 or mutated GPT2 alleles yielded viable gpt2::TRP1 sct1::HIS3 (2) 
cells. Ten fold dilutions of 2 cells containing GAL1 promoter driven GPT2 constructs with 
HA- or VSVG-epitopes inserted at positions 235 or 412 were plated on selective (-His, -Trp) or 
non-selective media containing amino acids, uracil, adenine, 5’-fluoroorotic acid (FOA) and 
galactose (YNBGal) or glucose (YPD) as indicated. Note that the low expression of Gpt2p-412-
VSVG and Gpt2p-412-HA on glucose is sufficient to rescue the lethality of the gpt2::TRP1 
sct1::HIS3 double mutation. B, samples denoted with 1 to 3 stars in Fig. 5A - C were run side by 
side in a single SDS-PAGE gel and different parts of the Western blot were probed with the 
appropriate antibodies. It appears that the larger fragments of Gpt2 proteins having tags at amino 
acids 235 or 412 are the same, suggesting that they encompass both tag insertion sites, 235 and 
412. The Gpt2p-412-VSVG produced a unique intermediate of about 50 kDa whereas the 
Gpt2p-235-VSVG and Gpt2p-235-HA produced a unique intermediate of about 44 kDa. Thus, 
the smaller fragments generated are different, as might be expected. Note that the unique 25-kDa 
fragment of Gpt2p-235-HA and Gpt2p-235- VSVG (Fig. 5A, B) was allowed to run out of the 
gel. 
 
Fig. S6. Phosphosites detected by mass spectrometry in purified Gpt2p. The two 
Coomassie blue stained bands corresponding to the upper and lower band of Gpt2p were 
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excised from an SDS-PAGE gel and processed for mass spectrometry as described in 
supplemental experimental procedures. This allowed to identify with high confidence the 
phosphosites that are underlain black; peptides identified are underlain in yellow, 
acyltransferase motifs I (79-86) and III (258-262) are in red, motifs II (137) and IV (271 or 
296) in green. Transmembrane helices predicted by TOPCONS global prediction are 
underlined.  
Fig. S7. GPAT activity in sct1 microsomes. A, 200 μl aliquots of microsomes (100 μg of 
protein) were preincubated for 1 h on ice without or with 0.1% TX-100, [14C]-G3P was added 
and samples were incubated for 2, 5, 10 and 20 min. Products were analyzed by TLC and lipids 
quantified by radioscanning. B, 0, 2.5, 6.4, 16, 40 and 100 μg of microsomal proteins from sct1 
cells were completed to total amount of 100 μg protein with boiled microsomes, preincubated 
for 1 hour on ice and GPAT activity was measured during 10 min as in panel A. C, aliquots of 
the aqueous phase of Folch separations performed on lipid extracts in the experiment of panel A 
were taken and analyzed by TLC on plastic supported cellulose (0.1 mm Cellulose Polygram 
CEL300, Macherey Nagel) using as a solvent MeOH/1 M NH4Ac pH8.5/0.2M EDTA 
(70/20/0.5). Quantification by radioscanning allowed to assess the percentage of [14C]G3P 
present at all moments either as a percentage of the sum of [14C]G3P + [14C]glycerol, or as 
percentage of the total radioactivity present in the lane. 
Supplemental Tables 
Table SI. Yeast strains and plasmids 
Name Genetic markers Source/reference 
Strains 
STY50 MATa his4-401 leu2-3,112 trp1-1 ura3-52 hol1-1 
SUC2::LEU2 
(Strahl-Bolsinger 
and Scheinost, 
1999) 
BY4742 MAT  his31 leu20 lys20 ura30  EUROSCARF  
W303-1B MAT , ade2-1 can1-100 ura3-1 leu2-3 112 trp1-1 his3-
11,15 
Paul Kirchmann  
gpt2/GPT2 
sct1/SCT1 
(FBY2250) 
MATa/  ura3/ura3 his3/his3 leu2/leu2 trp1/trp1 ade2/ade2 
can1/can1 gpt2::TRP1/GPT2 sct1::HIS3/SCT1 
This study 
gpt2 
(CMY204) 
MATa ura3-1 his3-1115 leu2-3112 trp1-1 ade2-1 can1-100 
gpt2::TRP1 
Christopher R. Mc 
Master 
sct1 
(CMY201) 
MAT  ura3-1 his3-1115 leu2-3112 trp1-1 ade2-1 can1-100 
sct1::HIS3 
Christopher R. Mc 
Master 
2.GPT2 
(FBY2252) 
ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 
containing plasmid pBF733 
This study 
2.GPT2-C77 ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 This study 
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(FBY7407) containing plasmid pBF736 
2.GPT2-C254 
(FBY7410) 
ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 
containing plasmid pBF730 
This study 
2.GPT2-C297 
(FBY7431) 
ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 
containing plasmid pBF737 
This study 
2.GPT2-235-
VSVG 
(FBY2259) 
ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 
containing plasmid pBF225 
This study 
2.GPT2-235-
HA (FBY7404) 
ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 
containing plasmid pBF223 
This study 
2.GPT2-412-
VSVG 
(FBY2255) 
ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 
containing plasmid pBF228 
This study 
2.GPT2-412-
HA (FBY2253) 
ura3 his3 leu2 trp1 ade2 can1 gpt2::TRP1 sct1::HIS3 
containing plasmid pBF227 
This study 
sct1  MAT  his31 leu20 lys20 ura30 ybl011w::KanMX 
 
EUROSCARF 
FBY2272 STY50 with pJK90 harboring GPT2-P109-HA-SUC2-
HIS4C  
(Kim et al., 2003) 
FBY2274 STY50 with pJK90 harboring GPT2-K120-HA-SUC2-
HIS4C 
(Kim et al., 2003) 
FBY7378 STY50 with pJK90 harboring GPT2-P259-HA-SUC2-
HIS4C 
(Kim et al., 2003) 
FBY7379 STY50 with pJK90 harboring GPT2-G262-HA-SUC2-
HIS4C 
(Kim et al., 2003) 
FBY7380 STY50 with pJK90 harboring GPT2-P333-HA-SUC2-
HIS4C 
(Kim et al., 2003) 
FBY7381 STY50 with pJK90 harboring GPT2-P467-HA-SUC2-
HIS4C 
(Kim et al., 2003) 
FBY2280  his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmid pBF649 (2x FLAG-GPI8) 
This study 
FBY2344 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF733 (WT GPT2) 
This study 
FBY2295 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF237 (GPT2-C77-254-297) 
This study 
FBY2289 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF233 (GPT2-C77-110-254-530) 
This study 
FBY2305 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF239 (GPT2-C77-254-530) 
This study 
FBY2306 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF240 (GPT2-C77-110-254) 
This study 
FBY2314 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF241 (GPT2-C77-99-254-297) 
This study 
FBY2315 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF242 (GPT2-C77-243-254-297) 
This study 
FBY2316 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF243 (GPT2-C77-250-254-297) 
This study 
FBY2317 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF244 (GPT2-C77-251-254-297) 
This study 
FBY2349 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF246 (GPT2-C77-254-297-349) 
This study 
FBY2351 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF248 (GPT2-C77-254-297-330-
331-332) 
This study 
FBY2352 his31, leu20, lys20, ura30, trp1::KanMX4 containing 
plasmids pBF649 and pBF249 (GPT2-C77-254-297-345-
346-347) 
This study 
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Plasmids 
pJK90 2μ, URA3, TPIUAS-HA-SUC2-HIS4C (Kim et al., 2003) 
pYES2NT/B 2μm, URA3 INVITROGEN 
pBF649 2x FLAG-GPI8 in pBF617, CEN/ARS, TRP1 I. Imhof 
pBF720 
 
GAL1UAS-GPT2-V5-His6 in pYES2NT/B containing an 
uncorrected N719D mutation 
This study 
pBF733  GAL1UAS-GPT2-V5-His6 in pYES2NT/B This study 
pBF736  GAL1UAS-GPT2-C77-V5-His6 in pYES2NT/B* 
 
This study 
pBF730  GAL1UAS-GPT2-C254-V5-His6 in pYES2NT/B* 
 
This study 
pBF737  GAL1UAS-GPT2-C297-V5-His6 in pYES2NT/B* 
 
This study 
pBF223 GAL1UAS-GPT2-235-HA-V5-His6 in pYES2NT/B This study 
pBF225 GAL1UAS-GPT2-235-VSVG-V5-His6 in pYES2NT/B This study 
pBF227 GAL1UAS-GPT2-412-HA-V5-His6 in pYES2NT/B This study 
pBF228 GAL1UAS-GPT2-412-VSVG-V5-His6 in pYES2NT/B This study 
pBF237  GAL1UAS-GPT2-C77-254-297-V5-His6 in pYES2NT/B* This study 
pBF233 GAL1UAS-GPT2-C77-110-254-C530-V5-His6 in 
pYES2NT/B* 
This study 
pBF239 GAL1UAS-GPT2-C77-254-530-V5-His6 in pYES2NT/B* This study 
pBF240 GAL1UAS-GPT2-C77-110-254-V5-His6 in pYES2NT/B* This study 
pBF241  GAL1UAS-GPT2-C77-99-254-297-V5-His6 in pYES2NT/B* This study 
pBF242  GAL1UAS-GPT2-C77-243-254-297-V5-His6 in pYES2NT/B* This study 
pBF243 GAL1UAS-GPT2-C77-250-254-297-V5-His6 in pYES2NT/B* This study 
pBF244  GAL1UAS-GPT2-C77-251-254-297-V5-His6 in pYES2NT/B* This study 
pBF246  GAL1UAS-GPT2-C77-254-297-349-V5-His6 in pYES2NT/B* This study 
pBF248 GAL1UAS-GPT2-C77-254-297-330-331-332-V5-His6 in 
pYES2NT/B* 
This study 
pBF249 GAL1UAS-GPT2-C77-254-297-345-346-347-V5-His6 in 
pYES2NT/B* 
This study 
* numbers indicate positions of all remaining cysteines (natural or substituted) present in the 
gpt2 allele carried by the vector. 
Table SII. Primers used for construction of different plasmids 
Num-
ber 
Purpose/name Sequence (5’-3’) 
918 Gpt2 forward aggtggtttgttacgcatgcaagcttgatatcgaaatgtctgctcccgctgccgatc 
1387 Gpt2-P109-DTR gatggtctagaggtgtaaccacttgagttcttaggaggcattctggatcggg 
1386 Gpt2-K120-DTR gatggtctagaggtgtaaccacttgagttcttaggtttcttaaaactcgactcagc 
919 Gpt2-P259-DTR gatggtctagaggtgtaaccacttgagttcttaggggggaaaatacctacacagcccttc 
920 Gpt2-G262-DTR gatggtctagaggtgtaaccacttgagttcttaggaccaccctcggggaaaatacctac 
921 Gpt2-P333-DTR gatggtctagaggtgtaaccacttgagttcttaggtggggagtccttatacatttcg 
922 Gpt2-P467-DTR gatggtctagaggtgtaaccacttgagttcttaggtggagtgaagagaatagaacc 
966 GPT2 amplification cagctaagcttataatgtctgctcccgctgcc 
967 GPT2 amplification cagctgcggccgctcgagttctttcttttcgtgttctcttttctgtcttac 
968 235 epitope insert. gcagagaaaggatccatcgacaatacggaaactttcca 
969 235 epitope insert. gtcgatggatcctttctctgcatatttaaaattagtaccattagtc 
970 412 epitope insert. ggtatatgacggatcctacaacaggaaattagattcagtggg 
971 412 epitope insert. cctgttgtaggatccgtcatataccagtttttttaagtgaataattct 
1003 HA epitope insert. gctgggatcctatccttacgatgttccagactacgcaggatccactt 
1004 HA epitope insert. aagtggatcctgcgtagtctggaacatcgtaaggataggatcccagc 
1005 VSVG epitope insert. acttggatcctatactgatattgaaatgaataggctaggtaaaggatccagtg 
1006 VSVG epitope insert. cactggatcctttacctagcctattcatttcaatatcagtataggatccaagt 
1338 GPT2 SCAM-C77S tgccaaccatccttgtgtctgcccctcatgcaaatcagttc 
1339 GPT2 SCAM-C110S tcccgatccagaatgccttcttttgttactgctgagtcgag 
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1340 GPT2 SCAM-C254S atcacttgcatacgaagggctctgtaggtattttccccgaggg 
1341 GPT2 SCAM-C297S tgaaagttgctgttgtaccctctggtttgcattatttccacag 
1343 GPT2 SCAM-C440A aaattagaagcattgagggcttttgtaactttgatcgttcg  
1344 GPT2 SCAM-C472A ttcactccaattttcattattgctcgcgtatactcagaaaagaagg 
1346 GPT2 SCAM-C530S tggcaagaaaacaacactattctcgcatctgggttccttcc  
1348 GPT2 SCAM-C603S tctagagttgactgctgtttctaacgatttaggacctttgg  
1520 GPT2 SCAM-S254C atcacttgcatacgaagggctgtgtaggtattttccccgaggg  
1342 GPT2 SCAM-S297C tgaaagttgctgttgtaccctgtggtttgcattatttccacag  
1538 GPT2 SCAM-T99C tcgggactttcccgctgagcacttcagcaaacgggtttg 
1540 GPT2 SCAM-Q243C gagaaaatcgacaatacggaaactttctgcagtgtttttgatcacttgcatacgaag 
1541 GPT2 SCAM-H250C atacctacacagcccttcgtacacaagtgatcaaaaacactctg 
1542 GPT2 SCAM-T251C tttccagagtgtttttgatcacttgcattgcaagggctgtgtaggt 
1546 GPT2 SCAM-F349C ctggagcattttcggtaacagaacacaaagaattggtgatcttttttag 
1544 GPT2 SCAM-
KDS330CCC 
gtggtggatgggaaatatggcgaaatgtattgttgctgcccacgtgagaccgtttccaaact
ac 
1543 GPT2 SCAM-
TNS345CCC 
tctggagcattttcggtaacagaaaacaaacaacagcagatcttttttagtagtttggaaacg
gtctc 
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Table SIII. Surface exposure predictions for native and substituted cysteines of Gpt2p 
Residue / 
Substitution 
Prediction Relative Surface 
Accessibility 
Absolute Surface 
Accessibility (ASA) 
ASA-mut/ 
ASA-nat 
Natural cysteines 
C77 B 0.019   2.597 - 
C110 B 0.089 12.552 - 
C254 B 0.076 10.642 - 
C297 B 0.015   2.148 - 
C440 B 0.190 26.620 - 
C472 B 0.039   5.448 - 
C530 B 0.209 29.316 - 
C603 B 0.020   2.752 - 
Cysteine substitutions 
T99C E / E 0.466 / 0.398   64.690 / 55.907 0.864 
Q243C E / E 0.461 / 0.467   82.317 / 65.581 0.797 
H250C E / E 0.576 / 0.517 104.811 / 72.643 0.693 
T251C E / E 0.700 / 0.697   97.062 / 97.831 1.008 
K330C 
D331C 
S332C 
E / E 
E / E 
E / E 
0.583 / 0.604 
0.651 / 0.640 
0.451 / 0.486 
119.861 / 84.858 
  93.795 / 89.926 
  52.822 / 68.262 
0.708 
0.959 
1.293 
T345C 
N346C 
S347C 
E / E 
E / E 
B / B 
0.272 / 0.241 
0.558 / 0.547 
0.176 / 0.190 
  37.754 / 33.879 
  81.706 / 76.757 
  20.639 / 26.606 
0.897 
0.939 
1.289 
F349C E / E 0.424 / 0.411   85.037 / 57.747 0.679 
Surface exposure of natural cysteines of Gpt2p and of amino acids that were replaced by 
cysteine were predicted using the predictor available at 
http://www.cbs.dtu.dk/services/NetSurfP. For substitutions, the relative and absolute values were 
obtained for the native and the mutated sequence and separated by a slash. Absolute surface 
accessibility (ASA) values (Petersen et al., 2009) are slightly diminished after the substitution of 
natural residues by cysteines, as indicated by the ratio “ASA-mutated/ASA-natural” ratio given 
in the last column. This ratio on average is 0.92.  
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